ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Anticipated Cost Savings of Using Lungs from Hepatitis C-Positive Lung Donors for Hepatitis C-Negative Recipients

K. Ryland1, J. Mallea2, J. Moriarty3, L. White4, B. Borah5, J. Naessens3

1Transplantation, Mayo Clinic, Jacksonville, FL, 2Medicine, Mayo Clinic, Jacksonville, FL, 3Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, 4Health Sciences Research, Mayo Clinic, Jacksonville, FL, 5Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2020 American Transplant Congress

Abstract number: 391

Keywords: Economics, Hepatitis C, Lung transplantation, Prediction models

Session Information

Session Name: Lung: Let's Start at the Beginning: Pre-Transplant Decision Making and Access to Lung Donors

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:27pm-3:39pm

Location: Virtual

*Purpose: We assessed the cost savings generated by additional organ availability due to utilizing lungs from hepatitis-C infected donors for transplantation in comparison to existing lung transplantation practice. By increasing organ availability and transplanting at lower LAS scores, healthcare costs could be reduced.

*Methods: We developed a Markov model using Monte Carlo microsimulation to obtain cost estimates for 1, 3, and 5-year timeframes for patients starting from the time of listing for lung transplantation. We included two arms, one for usual lung transplantation practice and an intervention arm allowing for 7% increased organ availability with acceptance of hepatitis C positive lung donation. Health states were stratified by four LAS categories: <40, ≥40 to <60, ≥60 to <80, and ≥80. Patients were allowed to move between LAS categories prior to transplantation. Model parameters, such as probabilities and costs, were obtained from existing literature on lung transplantation and internal lung transplant registries, supplemented by additional cost data from our practice. We simulated 100,000 hypothetical patients, with the model representing the average adult patient listed for a first lung transplant. Costs were valued in 2018 US Dollars. Future costs were discounted at 3% annually.

*Results: Mean costs of hepatitis C positive lung donation after 1 year is $166,944 compared with standard of care cost of $163,759, after 3 years is $217,120 compared with standard of care $216,430, and after 5 years is $218,031 compared with standard of care 5-year cost of $218,386. At each 1, 3, and 5-year time point, percentage of transplants increased using hepatitis C positive organs and percent deaths pre-transplant were reduced. Mean months alive were the same at 1, 3, and 5-years with increased organ availability. Time spent awaiting transplantation was reduced at each time point compared with standard of care. The biggest decreases in cost compared to standard of care were seen at LAS scores 60 to <80 and ≥80 at the 3 and 5-year time point.

*Conclusions: Use of lungs from donors infected with hepatitis C for transplantation increases organ availability and reduces wait time at a similar cost compared with existing lung transplantation practices. Cost savings are produced with longer timeframes, particularly as LAS score increases.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ryland K, Mallea J, Moriarty J, White L, Borah B, Naessens J. Anticipated Cost Savings of Using Lungs from Hepatitis C-Positive Lung Donors for Hepatitis C-Negative Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/anticipated-cost-savings-of-using-lungs-from-hepatitis-c-positive-lung-donors-for-hepatitis-c-negative-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences